Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study.
Goldberg
M
M
Theravance, Inc., South San Francisco, CA 94080, USA.
Li
Y-P
YP
Johanson
J F
JF
Mangel
A W
AW
Kitt
M
M
Beattie
D T
DT
Kersey
K
K
Daniels
O
O
D000328:Adult; D053961:Azabicyclo Compounds / Q000627:therapeutic use*; D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy*; D003672:Defecation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058828:Serotonin 5-HT4 Receptor Agonists / Q000627:therapeutic use*; D013223:Statistics as Topic; D016896:Treatment Outcome
D053961:Azabicyclo Compounds; D005765:Gastrointestinal Agents; D058828:Serotonin 5-HT4 Receptor Agonists; C533727:TD-5108